Seres Therapeutics Appoints Paul Biondi, Experienced Biopharmaceutical Strategy and Corporate Development Professional, to Its Board of Directors
“Seres is leading the development of microbiome therapeutics, a very promising new area of medicine. The Company has been on the forefront of implementing the highest quality clinical studies and of building field-leading drug discovery and manufacturing capabilities. I am honored to be joining the Board as the Company enters an exciting and potentially transformative period with two near-term, late-stage clinical readouts, as well as a number of additional earlier stage programs progressing forward,” said
Prior to joining Flagship,
“I look forward to partnering with Paul, a talented and deeply experienced corporate executive, to advance Seres’ pipeline as we work to bring transformative new medicines to patients,” said
“Paul brings strategic acumen, deep business development expertise and a wealth of biotech experience ahead of a potentially transformational period for the Company. I look forward to his contributions to Seres’ efforts to advance the burgeoning field of microbiome therapeutics,” said
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including the timing and results of each of Seres’ clinical studies, the promise and potential success of microbiome therapeutics, and other statements that are not historical facts.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: We have incurred significant losses, are not currently profitable and may never become profitable; our need for additional funding; our limited operating history; our unproven approach to therapeutic intervention; the lengthy, expensive, and uncertain process of clinical drug development; our ability to manufacture our product candidates, and develop and commercialize our product candidates, if approved; our ability to retain key personnel and to manage our growth; and that our management and principal stockholders have the ability to control or significantly influence our business. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200323005090/en/
PR
lisa@tenbridgecommunications.com
IR
ctanzi@serestherapeutics.com
Source:
PR
Lisa Raffensperger
lisa@tenbridgecommunications.com
IR
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com